ATSENA THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $150 MILLION SERIES C FINANCING
ATSENA THERAPEUTICS: FINANCING LED BY NEW INVESTOR BAIN CAPITAL
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.